IL-23 and axial disease: do they come together?
Document Type
Article
Publication Date
10-19-2021
Publication Title
Rheumatology (Oxford, England)
Keywords
washington; seattle; swedish
Abstract
IL-23 is a key cytokine in the pathogenesis of spondyloarthritides, including PsA and axial spondyloarthritis, as well as related conditions, such as psoriasis and IBD. Genetic associations, animal models and translational studies in humans demonstrate the key role played by IL-23, especially when coupled with downstream overexpression of IL-17 via stimulation of T helper 17 (Th17) and other cells by IL-23. Whereas IL-23 inhibition has shown clear-cut benefit in psoriasis and peripheral manifestations of PsA, trials of IL-23 inhibitors have failed in the treatment of ankylosing spondylitis. More recently, exploratory data from PsA patients with axial symptoms suggests that improvement may occur, but needs confirmation in dedicated axial spondyloarthritis (axSpA) trials. Hypotheses for these apparently conflicting findings about IL-23 inhibition in various forms of spondylitis are discussed.
Clinical Institute
Orthopedics & Sports Medicine
Department
Orthopedics
Department
Rheumatology
Recommended Citation
Mease, Philip and van den Bosch, Filip, "IL-23 and axial disease: do they come together?" (2021). Articles, Abstracts, and Reports. 5332.
https://digitalcommons.providence.org/publications/5332
